EPS for Sage Therapeutics, Inc. (SAGE) Expected At $-2.04

February 14, 2018 - By Marry Poplack

 EPS for Sage Therapeutics, Inc. (SAGE) Expected At $ 2.04
Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.23, from 0.98 in 2017Q2. It improved, as 33 investors sold Sage Therapeutics, Inc. shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported.
The California-based Schwab Charles Investment Mgmt Inc has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Proshare Ltd Liability Corporation reported 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Paloma Prns Mgmt holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 4,290 shares. Invesco Ltd stated it has 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Dekabank Deutsche Girozentrale holds 0.04% or 63,450 shares. Cwm Ltd Liability Corporation stated it has 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Rhumbline Advisers has 42,371 shares. Harbourvest Prns Limited Liability reported 11,319 shares. 1.09M were accumulated by Bb Biotech Ag. Moreover, Century Inc has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 25,343 shares. Fernwood Management Limited Company stated it has 0.33% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Victory Cap has 0.05% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 331,405 shares. Art Advsr Limited Liability Com holds 0.11% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 33,800 shares. Fred Alger Mgmt stated it has 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Northern Tru Corporation owns 412,174 shares.

Since December 14, 2017, it had 0 buys, and 2 selling transactions for $17.36 million activity. 44,000 shares were sold by Kanes Stephen, worth $7.80 million.

Analysts expect Sage Therapeutics, Inc. (NASDAQ:SAGE) to report $-2.04 EPS on February, 22.They anticipate $0.54 EPS change or 36.00 % from last quarter’s $-1.5 EPS. After having $-1.97 EPS previously, Sage Therapeutics, Inc.’s analysts see 3.55 % EPS growth. The stock increased 0.48% or $0.76 during the last trading session, reaching $160.1. About 1.06M shares traded or 14.90% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of SAGE in report on Thursday, December 7 with “Buy” rating. The stock has “Buy” rating by Canaccord Genuity on Monday, November 13. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Leerink Swann on Tuesday, June 20. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Friday, November 17 with “Outperform” rating. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, June 23 report. Raymond James upgraded the shares of SAGE in report on Wednesday, December 14 to “Strong Buy” rating. BMO Capital Markets maintained the shares of SAGE in report on Thursday, September 14 with “Outperform” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, September 3 by JP Morgan. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, November 16 by Bank of America. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Sell” rating given on Tuesday, May 24 by Chardan Capital Markets.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.29 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

More recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Nasdaq.com which released: “Commit To Buy Sage Therapeutics At $130, Earn 13.4% Using Options” on January 31, 2018. Also Nasdaq.com published the news titled: “Sage Therapeutics Reaches Analyst Target Price” on January 24, 2018. Prnewswire.com‘s news article titled: “Stock Review for Biotech’s Investors — Sage Therapeutics, Sarepta …” with publication date: February 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: